Antenatal Corticosteroid Therapy: Current Evidence and Practice

Antenatal corticosteroids remain one of the most important interventions for reducing complications associated with anticipated preterm birth. By accelerating fetal lung maturation and influencing several organ systems, these medicines can lower the incidence and severity of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and neonatal death in appropriately selected pregnancies.

The central clinical question is no longer simply whether corticosteroids should be given. Care teams must determine who is most likely to benefit, how soon birth may occur, which regimen is suitable, and whether maternal or fetal conditions alter the balance of benefit and risk. The effectiveness of treatment depends heavily on timing: a course given too early may have limited value by the time birth occurs, while treatment administered during an unrecognized infection may create avoidable harm.

The scientific program preserved through the FAOPS 2020 congress site reflected the importance of collaborative research in perinatal and neonatal medicine. Current practice continues to evolve as evidence expands beyond very preterm birth to include selected late-preterm pregnancies and, in carefully defined circumstances, the early edge of viability.

How Corticosteroids Improve Newborn Outcomes

Betamethasone and dexamethasone cross the placenta and stimulate maturation of the fetal lungs. They increase surfactant production, improve lung compliance, and reduce the likelihood that a newborn will need prolonged respiratory support. Their effects also extend to the brain and intestine, which helps explain reductions in intraventricular hemorrhage and necrotizing enterocolitis reported in preterm populations.

The greatest established benefit occurs when birth is expected within approximately seven days after treatment, although an exact prediction is impossible. Corticosteroids should therefore be considered when there is a credible risk of delivery rather than administered simply because a pregnancy has reached a particular gestational-age threshold.

A complete course does not guarantee an uncomplicated neonatal transition. Infants may still require continuous positive airway pressure, surfactant, intensive monitoring, or transfer to a higher-level unit. The therapy is one component of a broader strategy that includes timely referral, magnesium sulfate when indicated for neuroprotection, appropriate antibiotics, and preparation of neonatal staff and equipment.

Choosing Candidates By Gestational Age

For pregnancies at risk of preterm birth from around 24 through 34 weeks, antenatal corticosteroids are broadly recommended when delivery is likely within seven days and there is no evidence of maternal infection requiring immediate delivery. This recommendation applies across several pathways to birth, including spontaneous preterm labor, preterm prelabor rupture of membranes, and medically indicated early delivery.

The period from 34 weeks to 36 weeks and six days requires more individualized judgment. Evidence from the ALPS trial showed that a single course of betamethasone reduced respiratory support among selected late-preterm infants, but it also increased neonatal hypoglycemia. Treatment may be reasonable when late-preterm birth is highly likely within seven days, provided the clinical team can monitor and manage the newborn’s blood glucose.

At 22 or 23 weeks, evidence is less certain and practice varies by institution and family goals. Decisions should be integrated with counseling about resuscitation, expected survival, long-term morbidity, available neonatal care, and the timing of planned delivery. Gestational age alone should not replace shared decision-making in this range.

Timing, Regimens, And Repeat Courses

Common regimens include two 12-mg intramuscular doses of betamethasone 24 hours apart or four 6-mg intramuscular doses of dexamethasone 12 hours apart. If birth becomes unavoidable before the course is complete, treatment should generally begin rather than be withheld because the full schedule cannot be delivered. Even partial exposure may provide benefit, while urgent obstetric indications should never be delayed solely to finish corticosteroids.

The ideal interval between treatment and delivery is at least 24 hours, but benefit can occur when birth follows sooner. The effect gradually diminishes as time passes. For patients who remain at substantial risk of preterm birth seven or more days after an initial course, some guidelines support a single repeat, or “rescue,” course before 34 weeks. Repeated weekly courses or routine serial treatment are not recommended because potential fetal growth and developmental risks outweigh uncertain additional benefit.

A repeat course should be considered only after reviewing the original indication, current gestational age, interval since treatment, and the likelihood of delivery in the next week. Documentation should explain why the expected benefit justifies renewed exposure. This disciplined approach avoids treating the calendar rather than the clinical situation.

Infection, Ruptured Membranes, And Maternal Disease

Preterm prelabor rupture of membranes is not automatically a reason to withhold corticosteroids. When there is no clinical evidence of chorioamnionitis and preterm birth is plausible, a course is commonly offered alongside infection surveillance and other guideline-based management. Fever, uterine tenderness, maternal or fetal tachycardia, foul-smelling fluid, and laboratory findings may shift the priority toward delivery and antimicrobial treatment.

Infection deserves particular attention because corticosteroids can modify immune responses and may obscure clinical deterioration. Research examining placental pathology in COVID-19 pregnancy illustrates why placental inflammation, maternal illness, and fetal effects must be assessed together rather than treated as isolated issues. Current respiratory infection guidance generally supports corticosteroids when the expected obstetric or maternal benefit is clear, but the decision should account for disease severity, gestational age, and the urgency of birth.

Pregestational or gestational diabetes is another important consideration. Corticosteroids can produce significant maternal hyperglycemia, increase insulin requirements, and contribute to neonatal hypoglycemia. Diabetes is not necessarily a contraindication, but it calls for coordinated glucose management, clear insulin instructions, and postnatal monitoring. The same principle applies to other conditions in which fluid balance, infection risk, or metabolic control may be affected.

Safety Monitoring For Mother And Newborn

Maternal adverse effects are usually temporary but clinically meaningful. Hyperglycemia is common, and patients may experience flushing, sleep disturbance, or transient changes in blood pressure. Those with diabetes need a planned monitoring schedule rather than advice to check glucose only if symptoms appear. Medication adjustments should be coordinated between obstetric, diabetes, and anesthesia teams when delivery is imminent.

For the newborn, hypoglycemia is the clearest consistently observed concern, particularly after late-preterm exposure. Neonatal teams should identify infants who received antenatal corticosteroids, begin feeding and glucose surveillance according to local protocol, and treat low glucose promptly. A lower rate of respiratory morbidity does not remove the need for observation.

Questions about long-term neurodevelopment, growth, and cardiometabolic health remain important, especially with repeated exposure or treatment at very early gestational ages. Available evidence supports the use of a clinically indicated single course, while offering less reassurance for frequent repeat courses. Follow-up research should continue to distinguish the effects of corticosteroids from those of prematurity, infection, fetal growth restriction, and the underlying reason for early delivery.

Applying Evidence To Complex Pregnancies

Multiple pregnancy, fetal growth restriction, hypertensive disease, placenta previa, and planned early delivery can all alter the timing and expected benefit of treatment. For example, a patient with severe preeclampsia may need delivery before a complete course is possible; stabilizing the mother and preventing catastrophic complications takes priority. Steroids can be administered when feasible, but they should not postpone medically necessary birth.

Fetal growth restriction may increase concern about the effects of impaired placental function, yet it also increases the risk of preterm complications. The decision should consider Doppler findings, fetal surveillance, maternal condition, and whether delivery is expected soon. Similarly, in a pregnancy with twins or higher-order multiples, the evidence base is less extensive than for singleton gestations, but the risk of preterm birth often makes careful planning especially important.

Antenatal counseling should explain expected benefits in absolute as well as relative terms whenever possible. Families need to understand that corticosteroids improve the odds of respiratory and other neonatal outcomes; they do not prevent every complication or determine whether delivery should occur. Communication is strongest when clinicians describe the reason for treatment, the likely timing of birth, possible side effects, and the newborn monitoring plan in plain language.

Building A Reliable Clinical Protocol

Hospitals can improve outcomes by using a standardized eligibility checklist linked to local preterm birth pathways. The checklist should record gestational age, reason for anticipated birth, probability of delivery within seven days, previous courses, signs of infection, diabetes status, and the neonatal team’s readiness to monitor glucose and respiratory adaptation.

A protocol should also clarify who can authorize a repeat course, how urgent deliveries are handled, and when obstetric and neonatal consultations are required. Electronic prescribing prompts may reduce missed treatment opportunities, while audit data can identify inappropriate early administration, unnecessary repeat courses, and delays caused by transfers between facilities.

Key practice points include:

• Confirm that preterm birth is genuinely likely within seven days.
• Use a recognized betamethasone or dexamethasone regimen and document each dose.
• Screen for infection and do not postpone indicated delivery to complete treatment.
• Prepare for maternal hyperglycemia and neonatal hypoglycemia, especially in diabetes or late-preterm birth.
• Review any proposed repeat course against gestational age, previous exposure, and current delivery risk.

Effective antenatal corticosteroid therapy depends on disciplined selection, timely administration, and coordinated follow-up. Clinicians, researchers, and trainees can use the available FAOPS educational resources to keep perinatal discussions connected to wider evidence on placental biology, neonatal care, and pregnancy-related disease. Review local guidance, update prescribing pathways, and make each course a deliberate decision based on the patient’s current risk of birth.